Keywords: Janssen, Johnson & Johnson, Zytiga, UK, NICE, Prostate cancer

UK's NICE does U-turn, recommending Zytiga as Janssen cuts price

Article | 16 May 2012

Print This

UK drugs watch dog the National Institute for Health and Clinical Excellence (NICE) has reversed an earlier negative decision (The ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in